Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi

Sanofi ($SNY) is ramping up efforts to boost shareholder returns, announcing plans to repurchase up to €1 billion (about $1.20 billion) of its own ...

“Signal of Strength”: Sanofi (SNY) Launches €1 Billion Stock Buyback for 2026

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Quest Diagnostics (DGX – Research Report), Synergy CHC (SNYR – Re...

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Synergy CHC (SNYR) and Humana (HUM)

American automaker Ford ($F) and China’s smartphone giant Xiaomi ($HK:1810) have denied rumors of a joint venture to help the latter sell its elect...

Ford, Xiaomi Deny U.S. EV Partnership Rumors

In a report released on January 29, Nicolas Pauillac from Kepler Capital maintained a Hold rating on Sanofi, with a price target of €95.00. The com...

Kepler Capital  Keeps Their Hold Rating on Sanofi (SNYNF)

Sanofi SA (($SNY)) has held its Q4 earnings call. Read on for the main highlights of the call. Sanofi’s Earnings Call Balances Strong Growth With M...

Sanofi Earnings Call: Profitable Growth Amid Rising Risks

Jefferies analyst Benjamin Jackson CFA maintained a Buy rating on Sanofi today and set a price target of €100.00. According to TipRanks, Jackson CF...

Jefferies Sticks to Their Buy Rating for Sanofi (SNYNF)

Naturgy Energy Group SA ( ($GASNY) ) has issued an announcement. Naturgy Energy Group SA has announced it will publish its financial results for th...

Naturgy Sets Date to Publish 2025 Annual Results

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview: Sanofi is running a late-stage clinical trial titled “A Phase...

Sanofi Advances PCV21 Vaccine Trial in Sickle Cell Children, Targeting an Edge in Pneumococcal Protection

Naturgy Energy Group SA ( ($GASNY) ) has shared an update. Naturgy Energy Group SA has updated and formalised its internal Regulations governing th...

Naturgy Updates Board Governance Rules to Strengthen Oversight and Value Focus

Sanofi ($SNYNF) announced an update on their ongoing clinical study. Sanofi has completed a Phase 2 study titled “A Randomized, Double-blind, Place...

Sanofi Completes Key Amlitelimab Vaccine-Response Study in Atopic Dermatitis

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Apogee Therapeutics (APGE – Research Report) and Sanofi (SNYNF – ...

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE) and Sanofi (OtherSNYNF)

Sanofi ( ($SNY) ) just unveiled an update. On January 23, 2026, Sanofi reported new phase 3 data showing that its investigational monoclonal antibo...

Sanofi Advances Amlitelimab Toward Global Filings After Positive Phase 3 Atopic Dermatitis Data

In a report released today, Dan Levy from Barclays maintained a Sell rating on Polestar Automotive Holding UK, with a price target of $15.00. Accor...

Polestar Automotive Holding UK (PSNY) Receives a Sell from Barclays

An update from Sany Heavy Equipment International Holdings Co ( ($HK:0631) ) is now available. Sany Heavy Equipment International Holdings has ente...

Sany Heavy Equipment Signs RMB2 Billion Financial Products Framework with CICC

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immunocore Holdings (IMCR – Research Report), Sanofi...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Berenberg Bank analyst Luisa Hector reiterated a Buy rating on Sanofi yesterday and set a price target of €105.00. The company’s shares closed yest...

Sanofi (SNYNF) Receives a Buy from Berenberg Bank

In a report released yesterday, from Berenberg Bank maintained a Buy rating on Sanofi, with a price target of $62.00. The company’s shares closed y...

Berenberg Bank Keeps Their Buy Rating on Sanofi (SNY)

A new U.S.-EU trade war is brewing and could leave several European stocks across pharmaceutical, auto, and fashion possibly exposed. What’s Happen...

These European Stocks Could Be in the Firing Line in Trump’s Greenland Tariff War

Tesla ($TSLA) and brands owned by the Geely Group ($GELYF) are expected to be the primary winners after Canada decided to lower import taxes on ele...

Tesla & Geely Group Stock Set to Rally as First Winners of Canada’s EV Tariff Cut

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview Sanofi has launched a Phase 3 trial titled “A Phase 3, Randomi...

Sanofi Targets Pfizer’s Pneumococcal Stronghold With New Phase 3 Infant Vaccine Trial

Sanofi ($SNYNF) announced an update on their ongoing clinical study. Sanofi’s New Respiratory Vaccine Study Signals Next Wave of Multi-Pathogen Pro...

Sanofi Advances Next-Gen Respiratory Vaccines With Completed Phase 1 Multi-Virus Study

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Sanofi today and set a price target of €105.00. According to TipRanks, Papadaki...

Deutsche Bank  Reaffirms Their Buy Rating on Sanofi (SNYNF)

The latest update is out from Sany Heavy Equipment International Holdings Co ( ($HK:0631) ). Sany Heavy Equipment International Holdings has signed...

Sany Heavy Equipment Renews Connected Deposit Services Deal With Sanxiang Bank

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview Sanofi is running a Phase 1 study titled “A Phase 1, Multicent...

Sanofi Advances Balinatunfib With New Cardiac Safety Study in Healthy Volunteers

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview Sanofi has launched a post‑marketing safety study titled “Post...

Sanofi Targets Senior Flu Market With New Efluelda Safety Study in Korea

Traders will find all of the earnings, analyst ratings, and deals driving the stock market on Friday.


Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Shares in Tesla’s ($TSLA) Swedish&nbsp;electric vehicle&nbsp;rival Polestar ($PSNY)&nbsp;failed to get off the ground despite reporting its “best y...

Tesla Rival Polestar Stock (PSNY) Drops despite ‘Best Year’ Sales in 2025

An announcement from Polestar Automotive Holding UK PLC Sponsored ADR Class C ( ($PSNYW) ) is now available. Polestar Automotive Holding UK PLC, th...

Polestar Posts Record 2025 Retail Sales and Restores Nasdaq Listing Compliance

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview Sanofi is launching a Phase 3 trial titled “A Randomized, Phas...

Sanofi Advances Frexalimab With New Phase 3 Study of Subcutaneous vs. IV Dosing in Multiple Sclerosis

Barclays analyst Shirley Chen downgraded Sanofi to a Hold today and set a price target of €85.00. According to TipRanks, Chen is ranked #4918 out o...

Sanofi (SNYNF) was downgraded to a Hold Rating at Barclays

Sanofi ($SNYNF) announced an update on their ongoing clinical study. Study Overview Sanofi is running a major late-stage trial called PERSEUS, offi...

Sanofi’s PERSEUS PPMS Trial Nears Key Inflection Point for Tolebrutinib and MS Market

Sanofi (SNY) Gets a Buy from Berenberg Bank

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on Sanofi, with a price target of €105.00. The company’s s...

Berenberg Bank Reaffirms Their Buy Rating on Sanofi (SNYNF)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bioxcel Therapeutics (BTAI – Research Report), Sanofi (SNYNF – Re...

Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI), Sanofi (OtherSNYNF) and Siemens Healthineers AG (OtherSEMHF)

Regeneron Pharmaceuticals ($REGN), Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview: Sanofi and Regeneron have ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SNY	$47.38	+0.22%	2.99M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SNY	$47.38	+0.2%	2.99M
3
4
5
6

SNY

SNY

No Data Available

Get Sanofi Data in Excel

Get Sanofi Data in Excel